Amylin (AMLN) +6% to $27.19 on reports that it's attracted multiple suitors. Leerink Swann...

|By:, SA News Editor

Amylin (AMLN) +6% to $27.19 on reports that it's attracted multiple suitors. Leerink Swann analysts reckon Sanofi (SNY) and Merck (MRK) will emerge as the strongest bidders, and predict a sale price in the mid-$30 a share, although it could go higher if there's a bidding war for the biotech firm.